Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 5.050-5.200 for the period, compared to the consensus EPS estimate of 5.070. The company issued revenue guidance of $4.5 billion-$4.6 billion, compared to the consensus revenue estimate of $4.4 billion.

Analyst Ratings Changes

Several brokerages have recently weighed in on ILMN. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Canaccord Genuity Group raised their price objective on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Barclays upped their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Finally, Evercore ISI restated an “outperform” rating and issued a $155.00 price objective on shares of Illumina in a report on Monday, January 5th. Six investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $127.18.

Illumina Stock Performance

ILMN stock traded down $0.58 on Thursday, hitting $133.61. The company had a trading volume of 2,969,839 shares, compared to its average volume of 2,009,389. The stock has a market cap of $20.42 billion, a price-to-earnings ratio of 30.78, a P/E/G ratio of 2.23 and a beta of 1.45. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The stock’s 50-day simple moving average is $138.59 and its 200 day simple moving average is $115.87. Illumina has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.13. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the business posted $0.95 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.60% of the stock is owned by company insiders.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. Parallel Advisors LLC raised its stake in Illumina by 4.7% during the third quarter. Parallel Advisors LLC now owns 2,834 shares of the life sciences company’s stock valued at $269,000 after purchasing an additional 128 shares in the last quarter. Zacks Investment Management lifted its holdings in shares of Illumina by 0.6% in the 3rd quarter. Zacks Investment Management now owns 24,655 shares of the life sciences company’s stock valued at $2,342,000 after acquiring an additional 143 shares during the last quarter. Prelude Capital Management LLC grew its position in Illumina by 11.2% in the third quarter. Prelude Capital Management LLC now owns 2,770 shares of the life sciences company’s stock worth $263,000 after acquiring an additional 279 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in Illumina by 0.6% during the third quarter. Public Employees Retirement System of Ohio now owns 49,420 shares of the life sciences company’s stock valued at $4,693,000 after purchasing an additional 307 shares during the period. Finally, NewEdge Advisors LLC raised its position in Illumina by 12.4% during the third quarter. NewEdge Advisors LLC now owns 3,073 shares of the life sciences company’s stock valued at $292,000 after purchasing an additional 338 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.